NovaBridge Biosciences (NBP)
| Market Cap | 260.21M +273.4% |
| Revenue (ttm) | n/a |
| Net Income | -88.34M |
| EPS | -0.92 |
| Shares Out | 115.65M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,178,506 |
| Open | 2.400 |
| Previous Close | 2.380 |
| Day's Range | 2.250 - 2.450 |
| 52-Week Range | 0.833 - 6.790 |
| Beta | 1.56 |
| Analysts | Strong Buy |
| Price Target | 9.00 (+300.0%) |
| Earnings Date | Aug 21, 2026 |
About NBP
NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, imp... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to one analyst, the rating for NBP stock is "Strong Buy" and the 12-month stock price target is $9.0.
News
NovaBridge Appoints Mark Hagler as President and Chief Commercial Officer to Advance Commercial Strategy and Maximize Pipeline Value
Seasoned Biopharma leader bringing deep commercial experience to shape and inform corporate strategy, clinical trial design and business development discussions Strong industry reputation and commerci...
NovaBridge Reports Full Year 2025 Financial Results and Provides Business Update
ROCKVILLE, Md., April 07, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (“NovaBridge” or the “Company”), a global biotechnology platform company committed to accelerating access to inn...
NovaBridge Announces Productive FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer
FDA confirmed givastomig's potential eligibility for an accelerated approval pathway NovaBridge expects to initiate a registrational Phase 3 combination trial as early as Q4 2026, using objective resp...
NovaBridge Biosciences Transcript: Leerink Global Healthcare Conference 2026
The company has pivoted to a platform model leveraging China-U.S. synergies, with Givastomig showing strong efficacy and safety in gastric cancer and VIS-101 demonstrating superior durability in AMD. IPO plans are delayed pending regulatory and market conditions.
Mid-Cap NovaBridge Biosciences Stock Jumps Fueled By Positive Study Data In Eye Disease
NovaBridge Biosciences (NASDAQ: NBP) shares are up on Monday following the announcement of positive topline results from the Phase 2a study of VIS-101, a treatment for retinal vascular diseases.
NovaBridge Biosciences Transcript: Status update
VIS-101 demonstrated strong safety, rapid and durable efficacy in phase IIa for retinal vascular diseases, with up to 70% of patients retreatment-free at four months. A phase IIb dose-ranging study is planned, and a global phase III program will follow, supported by a robust financial position.
NovaBridge and Visara Announce Positive Results from VIS-101 Phase 2a Wet AMD Study
ROCKVILLE, Md., March 09, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovati...
NovaBridge to Host Business Update Call to Review Phase 2a Data for VIS-101 in Wet AMD on Monday, March 9, 2026
VIS-101, purpose-designed to be a best-in-class dual VEGF-A/ANG-2 inhibitor, has the potential to provide more effective and durable treatment than the current standard of care for patients with wet A...
NovaBridge to Present at the Leerink Partners 2026 Global Healthcare Conference
ROCKVILLE, Md., March 02, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovati...
NovaBridge Appoints Biotech Leader, Emmett T. Cunningham, Jr, MD, PhD, MPH, as Vice Chairman of the Board to Further Accelerate Global Biotech Platform
ROCKVILLE, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company), a global biotechnology platform company committed to accelerating access to innovati...
NovaBridge Doses First Patient in Global, Randomized Phase 2 Study of Givastomig Combined with Immunochemotherapy in Patients with 1L Metastatic Gastric Cancer
ROCKVILLE, Md., Feb. 17, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovativ...
NovaBridge Announces Open Market Purchases by Executive Chairman, Fu Wei
ROCKVILLE, Md., Jan. 20, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovativ...
NovaBridge Presents Positive Givastomig Dose Expansion Data from the Phase 1b Combination Study in Patients with 1L Metastatic Gastric Cancer
ROCKVILLE, Md., Jan. 06, 2026 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovativ...
NovaBridge to Ring the Nasdaq Opening Bell on Friday, January 2, 2026
NovaBridge Also Included in the Highly Regarded Nasdaq Biotech Index, Emphasizing its Position as an Industry Leader
NovaBridge Presents Positive Ragistomig Phase 1 Dose Expansion Data at ESMO-IO
ROCKVILLE, Md., Dec. 10, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovativ...
NovaBridge Announces Presentation of Ragistomig Expanded Phase 1 Data at ESMO-IO
ROCKVILLE, Md., Dec. 03, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovativ...
NovaBridge's Visara Subsidiary Appoints Distinguished Ophthalmology Leaders as Chief Medical Officer and Scientific Advisory Board Chair to Drive VIS-101 Forward
ROCKVILLE, Md., Nov. 20, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovativ...
NovaBridge Subsidiary Visara Assigns Its Exclusive License to Everest Medicines for VIS-101 in Greater China and Certain Other Asian Countries
ROCKVILLE, Md., Oct. 29, 2025 (GLOBE NEWSWIRE) -- NovaBridge Biosciences (Nasdaq: NBP) (NovaBridge or the Company) a global biotechnology platform company committed to accelerating access to innovativ...
I-MAB (Nasdaq: IMAB) Transitions to NovaBridge Biosciences (Nasdaq: NBP) with Trading Effective October 30, 2025 New Brand and Logo to Reflect Strategic Transformation to a Global Biotech Platform
New corporate brand reflects strategic transformation to a global biotech platform accelerating access to innovative medicines for patients worldwide Strategy centers on broadening access to global ca...
I-Mab To Present Positive Updated Givastomig Monotherapy Data at 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference on October 23, 2025
ROCKVILLE, Md., Oct. 22, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (I-Mab or the Company), is a global biotechnology platform company committed to accelerating access to innovative medicines for p...
NovaBridge Biosciences Transcript: Investor Update
A major transformation is underway, shifting to a global platform model that leverages Asian biotech innovation for global markets. The pipeline features promising oncology and ophthalmology assets, with a focus on rapid proof-of-concept and capital-efficient development. CBC Group's expertise and a hub-and-spoke structure underpin growth and value creation.
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
ROCKVILLE, Md., Oct. 16, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (I-Mab or the Company), a global biotechnology platform company committed to accelerating access to innovative medicines for pati...
I-Mab to Present Short-Talk on Updated Givastomig Monotherapy Data at the 2025 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference
ROCKVILLE, Md., Oct. 14, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatm...
NovaBridge Biosciences Transcript: H.C. Wainwright 27th Annual Global Investment Conference
Focused on U.S. clinical development, the lead asset Jeva Stomach shows strong efficacy and safety in front-line metastatic gastric cancer, with rapid trial enrollment and broad eligibility. A large phase two trial is set to launch, and expansion into other cancers is planned.
I-Mab Announces the Appointment of Seasoned Biotech Executives to the Board of Directors and the Scientific Advisory Board, and the Formation of a Research and Development Committee
ROCKVILLE, Md., Aug. 25, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ:IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatm...